Insulet (PODD) reported Q3 EPS of $0.45, $0.29 better than the analyst estimate of $0.16. Revenue for the quarter came in at $340.8 million versus the consensus estimate of $313.06...
Last August, a little section of U.S. President Joe Biden’s much-touted Inflation Reduction Act caught the attention of investors. It introduced a 1% tax on stock...
Insulet (NASDAQ:PODD) Corporation PODD announced first-quarter 2020 loss per share of 3 cents, declining from year-ago earnings per share (EPS) of 7 cents. The loss was wider than...
The April stock market rally was impressive, but can it carry into May? The performance of leading stocks next week is key. The past several months in the stock market were a wild...
Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Omnipod), the Omnipod DASHTM Insulin Management System (Omnipod DASH) and its digital mobile Omnipod platform. The Omnipod System features two devices: a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) and a Personal Diabetes Manager (PDM). Users has to fill the Pod with insulin and wear directly on the body. It can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back. The Pod delivers precise, personalized doses of insulin into the body through a small flexible tube, cannula. PDM is a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation.
|Average||320.94 (+10.91% Upside)|
|No. of Analysts||16|